Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0616 in Hypercholesterolemia (Phase 3, China)
CTR20233296Phase 3Completed
- Sponsor
- Not applicable
- Start
- Oct 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enlicitide in hypercholesterolemia, sponsored by Not applicable. Started Oct 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on CTR20233296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233296.